Asieris Received FDA IND Approval for CLDN6/9- ADC for the Treatment of Advanced Solid Tumors

Shanghai, China, August 13, 2026 – Asieris Pharmaceuticals (688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women health with significant unmet medical needs, announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of APL‑2501 (CLDN6/9-ADC), a novel asset independently developed […] The post Asieris Received FDA IND Approval for CLDN6/9- ADC for the Treatment of Advanced Solid Tumors appeared first on Asieris Pharmaceuticals .